What Medicare Agents Need to Know About the New GLP-1 Bridge Program
If you’ve turned on the news, opened social media, or spoken with clients lately, you’ve probably heard a lot about GLP-1 medications. Drugs like Wegovy and Zepbound have become some of the most talked-about medications in the country because of their ability to help people lose weight. As a result, many Medicare beneficiaries are asking the same question: Does Medicare cover GLP-1 medications?
Starting July 1, 2026, there may be a new answer to that question. The Centers for Medicare & Medicaid Services (CMS) is launching the Medicare GLP-1 Bridge Program, a temporary demonstration program designed to help eligible Medicare beneficiaries access certain GLP-1 weight-management medications.
Before you start discussing the program with clients, there are a few important things every agent should understand.
This Is Not a Medicare Advantage Benefit
The first and most important thing to know is that the GLP-1 Bridge Program is not a Medicare Advantage benefit and it is not a Medicare Part D plan benefit. The program is administered directly by Medicare.
That means Medicare, not the insurance carrier, determines eligibility, reviews prior authorization requests, and processes claims. This distinction is extremely important because beneficiaries may assume their Medicare Advantage plan or Part D plan is providing the coverage. Agents should be careful not to create that impression.
How the GLP-1 Medicare Program Works
The program is scheduled to begin on July 1, 2026, and run through December 31, 2027. If approved, eligible beneficiaries may be able to access certain weight-loss medications, including:
- Wegovy®
- Zepbound®
- Foundayo®
The expected member cost is $50 per monthly supply. Beneficiaries must be enrolled in a Medicare Part D plan to participate. Another important detail is that costs associated with the program do not count toward a member’s Part D out-of-pocket spending.
What Agents Should Say
As agents, our role is to educate and guide clients, not to determine eligibility. When a beneficiary asks about the program, keep the conversation simple and compliant. A good response might be:
“There is a new Medicare GLP-1 Bridge Program that may help eligible beneficiaries access certain weight-loss medications. The program is administered by Medicare, not your Medicare plan. If you’re interested, speak with your doctor to determine whether you may qualify.”
This keeps expectations realistic and directs beneficiaries to the appropriate source for clinical guidance.
What Agents Should Avoid Saying
Just as important as what you say is what you don’t say. Avoid statements like:
- “This Medicare Advantage plan covers Wegovy.”
- “You qualify for the program.”
- “I can get you approved.”
- “This is a new plan benefit.”
- “Carrier XYZ covers GLP-1 weight-loss medications.”
These statements could create confusion and potentially lead to compliance concerns. Remember, Medicare, not the agent and not the carrier, makes eligibility and approval decisions.
Expect More Questions
As awareness of the program grows, many agents will likely receive additional calls from current clients and prospects. While the GLP-1 Bridge Program itself is administered by Medicare, these conversations create valuable opportunities to strengthen client relationships. Use these interactions to:
- Review a beneficiary’s Medicare coverage.
- Confirm Part D enrollment.
- Discuss prescription drug needs.
- Identify other coverage gaps or planning opportunities.
- Reinforce your role as a trusted advisor.
Often, a simple question about one medication can lead to a broader conversation about a client’s overall healthcare needs.
The Bottom Line
The Medicare GLP-1 Bridge Program is expected to bring significant attention from beneficiaries looking for affordable access to weight-loss medications. As agents, the key is understanding what the program is, and what it isn’t.
Stay focused on education, set proper expectations, and direct beneficiaries to Medicare and their healthcare providers for eligibility and clinical questions.
Most importantly, use these conversations as an opportunity to provide guidance and strengthen client relationships. As CMS releases additional information, agents should continue monitoring updates and adjusting their conversations accordingly.
Bob Brzyski
Vice President of Marketing
